Pharmaceutical

ASCO 2024: Rakuten’s photoimmunotherapy and Keytruda combo shows efficacy in HNSCC

A Phase III trial evaluating Rakuten’s photoimmunotherapy in combination with Keytruda in recurrent HNSCC is planned for H2 this year.

May 29, 2024 - 04:00
ASCO 2024: Rakuten’s photoimmunotherapy and Keytruda combo shows efficacy in HNSCC
A Phase III trial evaluating Rakuten’s photoimmunotherapy in combination with Keytruda in recurrent HNSCC is planned for H2 this year.
Read the original article

Tags:

Previous Article

ASCO 2024: J&J’s early radioligand prostate cancer trial reports four patient de...

Next Article

Asahi Kasei offers to buy Sweden’s Calliditas for $1.04bn

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Risk adjusted net present value: What is the current valuation of Rocket Pharmaceuticals’s RPA-501?

Risk adjusted net present value: What is the current va...

Nov 18, 2023

STAT+: Pharmalittle: Vertex and U.K. at odds over value of CF meds; French authorities probe Sanofi over alleged market manipulation

STAT+: Pharmalittle: Vertex and U.K. at odds over value...

Nov 7, 2023

Prodrugs and patents: Enhancing therapy adherence and reducing side effects 

Prodrugs and patents: Enhancing therapy adherence and r...

Sep 12, 2024